Lung Cancer
Volume 45 , Pages S35-S36 , August 2004

Pathology of malignant mesothelioma

References 

  1. Dhaene K, Hubner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax. 1998;53:915–918
  2. Dhaene K, Wauters J, Weyn B, Timmermans JP, Van Marck E. Expression profile of telomerase subunits in human pleural mesothelioma. J. Pathol. 2000;190:80–85
  3. King JE, Hasleton PS. Commentary. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology. 2001;38:471–476
  4. Kumaki F, Kawai T, Churg A, Galateau-Salle FB, Hasleton P, Henderson D, et al.  Expression of telomerase reverse transcriptase (TERT) in malignant mesothelioma. Am. J. Surg. Pathol. 2002;26:365–370
  5. Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, et al.  WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J. Pathol. 1997;181:67–74
  6. Ramael M, Buysse C, van den Bossche J, Segers K, Van Marck E. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol. 1992;167:1–4
  7. Ramael M, van den Bossche J, Buysse C, van Meerbeeck J, Segers K, Vermeire P, et al.  Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J. Pathol. 1992;167:5–8

PII: S0169-5002(04)00169-2

doi: 10.1016/j.lungcan.2004.04.006

Lung Cancer
Volume 45 , Pages S35-S36 , August 2004

Article Tools